**Proteins** 

## **Product** Data Sheet

## Aminooxy-PEG3-C2-thiol

Cat. No.: HY-134512 CAS No.: 1200365-63-4 Molecular Formula:  $C_8H_{19}NO_4S$ Molecular Weight: 225.31

Target: **PROTAC Linkers** 

Pathway: **PROTAC** 

Storage: Powder -20°C 3 years

> In solvent -80°C 6 months

> > -20°C 1 month

| HS 0   | ·o^ | ~°~ | $\sim_{O^{NH_2}}$ |
|--------|-----|-----|-------------------|
| HS ~ ~ | O   | ~ ~ | O                 |

## **SOLVENT & SOLUBILITY**

| Vitro |
|-------|
|       |
|       |
|       |

DMSO: 100 mg/mL (443.83 mM; Need ultrasonic)

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 4.4383 mL | 22.1916 mL | 44.3833 mL |
|                              | 5 mM                          | 0.8877 mL | 4.4383 mL  | 8.8767 mL  |
|                              | 10 mM                         | 0.4438 mL | 2.2192 mL  | 4.4383 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

| Description               | $Aminooxy-PEG3-C2-thiol\ is\ a\ PEG-based\ PROTAC\ linker\ that\ can\ be\ used\ in\ the\ synthesis\ of\ PROTACs^{[1]}.$  |
|---------------------------|--|
| IC <sub>50</sub> & Target | PEGs   |
| In Vitro                  | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| FERENCES                    |  |
|-----------------------------|--|
| An S, et al. Small-molecule | PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             | Caution: Product has not been fully validated for medical applications. For research use only.                               |
|                             | Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com  |
|                             | Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA   |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |
|                             |  |

Page 2 of 2 www.MedChemExpress.com